ARAY
Accuray Incorporated
ARAY's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over ARAY overall, supported by lower modeled downside and stronger fundamentals.
ARAY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Weak |
ARAY's revenue, profitability, cash flow and balance sheet are all currently under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ARAY PE Valuation
ARAY has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ARAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect ARAY's losses to shrink, with revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ARAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.00 | +$0.40 |
| Q2 2026 | -$16.00 | -$15.20 |
| Q1 2026 | -$14.80 | -$14.80 |
| Q4 2025 | -$11.60 | -$9.60 |
| Q3 2025 | -$6.40 | +$0.40 |
| Q2 2025 | -$0.80 | +$5.60 |
| Q1 2025 | $0.00 | +$8.80 |
| Q4 2024 | -$2.00 | +$4.00 |
ARAY lost $6.00 per share over the past year, about the same as its loss the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ARAY on earnings quality, reporting a profit while its opponent remains loss making.
ARAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $86.5M | -7.9% |
| Q2 2026 | $100.9M | -21% |
| Q1 2026 | $104.8M | -7.4% |
| Q4 2025 | $102.2M | -12% |
| Q3 2025 | $93.9M | -7.5% |
| Q2 2025 | $127.5M | -5% |
| Q1 2025 | $113.2M | +12% |
| Q4 2024 | $116.2M | +8.3% |
ARAY's revenue has slid since its 2024 peak: $87M last quarter, down 7.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -42% | -30 points |
| Q2 2026 | 5.5% | +2.1 points |
| Q1 2026 | -8.7% | -9.6 points |
| Q4 2025 | -11% | -15 points |
| Q3 2025 | -12% | -9.9 points |
| Q2 2025 | 3.3% | -1.8 points |
| Q1 2025 | 0.9% | +5.4 points |
| Q4 2024 | 4% | +7.8 points |
ARAY's operating margin was −42% last quarter, down 30 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ARAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ARAY on profitability, with a higher operating margin.
ARAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9M | -138% |
| Q2 2026 | $2M | +$13M |
| Q1 2026 | -$6.1M | -136% |
| Q4 2025 | -$19M | -2151% |
| Q3 2025 | $10.3M | +$18.7M |
| Q2 2025 | -$11M | -217% |
| Q1 2025 | $17.1M | +$26M |
| Q4 2024 | $927K | +$7.3M |
ARAY's free cash flow was −$27M over the past year, against $17M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ARAY on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 17.8x | High |
| Q2 2025 | 6.6x | High |
| Q1 2025 | 6.3x | High |
| Q4 2024 | 11.1x | High |
| Q3 2024 | 52.6x | High |
| Q2 2024 | 17.4x | High |
| Q4 2023 | 21.3x | High |
| Q3 2023 | 9.3x | High |
ARAY's net debt is about 18 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ARAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.4 | Oversold |
| Stochastic | 3.2 | Oversold |
ARAY's weekly RSI is 26 (oversold) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ARAY PE vs Healthcare Sector
| Metric | ARAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARAY has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ARAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.69 | 54% below |
| 20 week MA | $8.94 | 66% below |
| 50 week MA | $16.9 | 82% below |
| 100 week MA | $40.9 | 92% below |
| 200 week MA | $72.4 | 96% below |
ARAY is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ARAY on trend strength, trading above more of its moving averages.
ARAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $112.8 | $177.2 | +57% |
| 2021 | $177.2 | $195.6 | +10% |
| 2022 | $195.6 | $79.2 | -60% |
| 2023 | $79.2 | $113.2 | +43% |
| 2024 | $113.2 | $73.2 | -35% |
| 2025 | $73.2 | $33.0 | -55% |
| 2026 YTD | $33.0 | $3.08 | -91% |
ARAY has finished lower in three of the last six years. It's down 91% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ARAY on returns for 2026, with the stronger performance.